A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
Phase I Trial to Investigate Safety and Tolerability Profile and Pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yuankai Shi, MD
- Phone Number: 86(10)87788293
- Email: syuankaipumc@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital Chinese Academy of Medical Sciences
-
Contact:
- Yuankai Shi, MD
- Phone Number: 86(10)87788293
- Email: syuankaipumc@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed advanced or metastatic solid tumor for which standard therapy does not exist, has failed, or has been refused.
- c-MET positive patients preferred in dose escalation phase; c-MET of patients must fulfill ICH++~+++ or FISH≥4 times in dose expansion phase.
- Confirmed that there are at least 1 can be measured in accordance with the standard RECIST1.1 by CT or MRI.
- 18 ~65 years of age.
- ECOG performance status of 0~1.
- Life expectancy of at least 3 months.
- Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (except alopecia).
Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below:
- Absolute neutrophil count (ANC) ≥ 1500/μL
- Platelet count ≥ 100000/μL
- Hemoglobin ≥ 9.0 g/dL
Acceptable liver function defined below:
- Total bilirubin ≤ 2 times upper limit of normal range (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN; however, ≤ 5 times ULN in a subject who has liver metastases
Acceptable renal function defined below:
- Serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) ≥ 60 mL/minutes
Acceptable coagulation status defined below:
- Prothrombin time < 1.5 times ULN
- Partial thrombin time < 1.5 times UL
- HIV Ag/Ab(-).
- HCV Ab(-);or HCV Ab(+) but HCV RNA(-).
- HBsAg(-)and HBcAb(-)in dose escalation phase;HBV DNA<1×103copies/ml if HBsAg(+)or HBcAb(+)in dose expansion phase.
- Ability to understand the purposes and risks of the trial and his/her informed consent using the human research ethics committee (HREC) approved informed consent form was obtained before the entering the trial.
Exclusion Criteria:
- Treatment with other c-MET TKI( specific target or multi-target);
- Anti-cancer treatment with radiation therapy(not including non target lesions receiving palliative radiotherapy), chemotherapy,hormonotherapy or surgery(small surgery, including the implantation of external equipment or fine needle aspiration, at least 7 days; diagnostic or palliative surgery, at least 14 days) within 4 weeks (6 weeks for nitrosoureas or Mitomycin C)prior to trial entry.
- Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
- Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease.
- Symptomatic brain metastases or unstable brain metastases (notes: Patients with asymptomatic brain metastases previously treated for the study, but must be kept stable for at least 4 weeks and receive a stable dose of the drug)
- Obvious neurological and mental disorder.
- Other previous or concomitant tumors (except for the effective treatment of melanoma, cervical carcinoma in situ, ductal carcinoma in situ or malignant tumor after effective treatment, remission 3 years and considered to have been cured).
- Active, uncontrolled bacterial, fungal infections, requiring systemic therapy.
- Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 0.5 year of trial entry)
- History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation.
- Participation in an investigational drug or device trial within 4 weeks prior to the trial entry.
- Anti-cancer treatment with radiation therapy, chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry.
- Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery
- Taking a medication that is a moderate or strong inhibitor or inducer of CYP2C9; taking a medication that prolongs QT interval and has a risk of Torsades de Pointes .
- Pregnant (positive serum beta human chorionic gonadotropin [β-HCG] test at Screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment.
- Known drug abuse or alcohol abuse.
- Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HS-10241 100mg
HS-10241 100mg daily
|
|
|
Experimental: HS-10241 200mg
HS-10241 200mg daily
|
|
|
Experimental: HS-10241 400mg
HS-10241 400mg daily
|
|
|
Experimental: HS-10241 600mg
HS-10241 600mg daily
|
|
|
Experimental: HS-10241 800mg
HS-10241 800mg daily
|
|
|
Experimental: HS-10241 1000mg
HS-10241 1000mg daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
MTD of HS-10241 based on the incidence of dose limiting toxicities
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Elimination half-life(T1/2) of HS-10241
Time Frame: 4 weeks
|
4 weeks
|
|
Progression-free survival (PFS)
Time Frame: 12 months
|
12 months
|
|
Max concentration (Cmax) of HS-10241
Time Frame: 4 weeks
|
4 weeks
|
|
Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Time Frame: 8 weeks
|
8 weeks
|
|
Incidence and intensity of Adverse Events according to Common Toxicity Criteria for AEs (CTCAE version 4.0)
Time Frame: 8 weeks
|
8 weeks
|
|
Area under the plasma concentration versus time curve (AUC) of HS-10241
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HS-10241-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.